Zydus Lifesciences reported a strong performance for the third quarter of the financial year 2024-25, with its consolidated net profit rising 30% year-on-year to ₹1,023 crore. The company had posted a net profit of ₹789 crore in the same quarter last year.
Revenue from operations saw a 17% growth, reaching ₹5,269 crore in Q3 FY25, compared to ₹4,505 crore in the year-ago period. The company attributed this strong performance to higher sales in both domestic and US markets.
Managing Director Sharvil Patel highlighted that the company’s growth was driven by strong execution in the US, an increase in market share in key therapy segments in India, and a well-positioned international portfolio. He also mentioned that Zydus Life remains on track to achieve double-digit growth and improved profitability for the full fiscal year.
At around 2:30 pm, stocks of Zydus Lifesciences traded at a price level of ₹978.45 at NSE, a 0.46% gain over its closing price yesterday.
Do you have a news tip for Lakshmishree reporters? Please email us at media@lakshmishree.com.
Source: Moneycontrol.
News Desk
